To Evaluate the Tolerance, pd, and pk of Lanthanum Polystyrene-sulfonate Powder in a Phase Ib/ IIa Clinical Trial in Patients With ESRD-HD Hyperphosphatemia With Multi-center, Multi-dose, Give the Drug Multiple Time
Latest Information Update: 05 Jul 2023
At a glance
- Drugs Lanthanum polystyrene sulfonic acid (Primary) ; Lanthanum carbonate
- Indications Hyperphosphataemia
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Liaoning Grand Nuokang Biopharmaceutical Co., Ltd.
Most Recent Events
- 02 Jun 2021 Planned End Date changed from 29 Apr 2022 to 31 Dec 2022.
- 02 Jun 2021 Planned primary completion date changed from 31 Dec 2021 to 30 Jun 2022.
- 27 Oct 2020 Status changed from not yet recruiting to recruiting.